Bulgaria's Sopharma Posts Flattish H1 Non-Cons Net Profit, Revenue Edges Up

Bulgaria's Sopharma Posts Flattish H1 Non-Cons Net Profit, Revenue Edges Up

Bulgarian drug maker Sopharma said on Tuesday that its non-consolidated net profit edged up to 25.0 million levs ($14.3 million/12.8 million euro) in the first half of 2019, from 24.9 million levs in the same period of 2018.As at 13:05 CET on Tuesday, Sopharma shares traded 0.60% lower at 3.29 levs on the Bulgarian Stock Exchange. Sopharma's drug sales revenue rose by a slim 1% year-on-year to 100.2 million levs in the first six months of the year, supported by higher sales in Europe, the company said in an interim financial statement. The company's European sales grew 13% on the year to 53.0 million levs in the review period, backed by a 35% rise in exports to Ukraine and a 7% increase in sales in Russia. Sales in Bulgaria dropped 11% to 38.0 million levs.

Previous Next
Close
Test Caption
Test Description goes like this
Cookies Preferences
Choose Type of Cookies You Accept Using


These cookies are required for the website to run and cannot be switched off. Such cookie are only set in response to actions made by you such as language, currency, login session, privacy preferences. You can set your browser to block these cookies but our site may not work then.


These cookies allow us to measure visitors traffic and see traffic sources by collecting information in data sets. They also help us understand which products and actions are more popular than others.


These cookies are usually set by our marketing and advertising partners. They may be used by them to build a profile of your interest and later show you relevant ads. If you do not allow these cookies you will not experience targeted ads for your interests.